NAD+ in Aging: Molecular Mechanisms and Translational Implications

Trends in Molecular Medicine

Volumn 23, Issue 10, 2017, Pages 899-916

  Fang, Evandro F ^a,b,c   Lautrup, Sofie ^a,c   Hou, Yujun ^a   Demarest, Tyler G ^a   Croteau, Deborah L ^a   Mattson, Mark P ^a,d   Bohr, Vilhelm A ^a,e  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c AARHUS UNIVERSITY   (Denmark)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

aging; autophagy; clinical application; DNA repair; metabolism; mitophagy; NAD+; neurodegenerative disorder; stem cell

Indexed keywords

3 AMINOBENZAMIDE 3,4 DIHYDRO 5 [4 (1 PIPERIDINYL)BUTOXY] 1(2H)ISOQUINOLINE; ACIPIMOX; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE RIBOSIDE; SIRTUIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AUTOPHAGY; CARDIOVASCULAR DISEASE; DNA REPAIR; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEARING IMPAIRMENT; HUMAN; LIFESPAN; METABOLIC DISORDER; MUSCLE ATROPHY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE METABOLISM; PARKINSON DISEASE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; ENERGY METABOLISM; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; HUMANS; MUSCULAR ATROPHY; NAD; PARKINSON DISEASE;

EID: 85028926903     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.08.001     Document Type: Review

References (126)

1. Nobel Media AB, Eduard Bunchner – Facts. 2014 Nobelprize.org.
2. Harden, A., Young, W.J., The alcoholic ferment of yeast-juice. Part II. The coferment of yeast-juice. Proc. R. Soc. Lond. B, 1906, 369–375.
3. James, L.K., Nobel Laureates in Chemistry 1901–1992. 1993, Merck & Co.
4. Boyer, Paul D., The Enzymes. 3rd edn, 1970, Academic Press.
5. Kornberg, A., Pricer, W.E. Jr, On the structure of triphosphopyridine nucleotide. J. Biol. Chem. 186 (1950), 557–567.
6. Euler-Chelpin, H.V., Fermentation of sugars and fermentative enzymes. Nobel Lectures, Chemistry 1922–1941, 1966, Elsevier, 144–155 https://www.nobelprize.org/nobel_prizes/chemistry/laureates/1929/euler-chelpin-lecture.pdf.
7. Wallace, D.C., Mitochondria and cancer. Nat. Rev. Cancer 12 (2012), 685–698.
8. + in aging, metabolism, and neurodegeneration. Science 350 (2015), 1208–1213.
9. Canto, C., et al. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22 (2015), 31–53.
10. Chalkiadaki, A., Guarente, L., The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15 (2015), 608–624.
11. Bonkowski, M.S., Sinclair, D.A., Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat. Rev. Mol. Cell Biol. 17 (2016), 679–690.
12. Kerr, J.S., et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 40 (2017), 151–166.
13. Rubinsztein, D.C., et al. Autophagy and aging. Cell 146 (2011), 682–695.
14. Fang, E.F., et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157 (2014), 882–896.
15. Belenky, P., et al. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129 (2007), 473–484.
16. Yang, H., et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130 (2007), 1095–1107.
17. Cambronne, X.A., et al. Biosensor reveals multiple sources for mitochondrial NAD(+). Science 352 (2016), 1474–1477.
18. Canto, C., et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458 (2009), 1056–1060.
19. Uddin, G.M., et al. Head to head comparison of short-term treatment with the NAD(+) precursor nicotinamide mononucleotide (NMN) and 6 weeks of exercise in obese female mice. Front. Pharmacol., 7, 2016, 258.
20. Mitchell, S.J., et al. Effects of sex, strain, and energy intake on hallmarks of aging in mice. Cell Metab. 23 (2016), 1093–1112.
21. Fukuwatari, T., et al. Elevation of blood NAD level after moderate exercise in young women and mice. J. Nutr. Sci. Vitaminol. (Tokyo) 47 (2001), 177–179.
22. Verdin, E., NAD(+) in aging, metabolism, and neurodegeneration. Science 350 (2015), 1208–1213.
23. Conforti, L., et al. Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. FEBS J. 278 (2011), 2666–2679.
24. Zhai, R.G., et al. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 452 (2008), 887–891.
25. Gilley, J., Coleman, M.P., Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol., 8, 2010 e1000300.
26. Revollo, J.R., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6 (2007), 363–375.
27. Imai, S., Yoshino, J., The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes. Metab. 15:Suppl 3 (2013), 26–33.
28. Frederick, D.W., et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle. Cell Metab. 24 (2016), 269–282.
29. Nakagawa, T., Guarente, L., Sirtuins at a glance. J. Cell Sci. 124:Pt 6 (2011), 833–838.
30. Ramsey, K.M., et al. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7 (2008), 78–88.
31. Imai, S., Guarente, L., NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24 (2014), 464–471.
32. Rouleau, M., et al. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10 (2010), 293–301.
33. Aksoy, P., et al. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. Res. Commun. 345 (2006), 1386–1392.
34. Adebanjo, O.A., et al. A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis. Nat. Cell Biol. 1 (1999), 409–414.
35. Fang, E.F., et al. Nuclear DNA damage signalling to mitochondria in ageing. Nat. Rev. Mol. Cell Biol. 17 (2016), 308–321.
36. Escande, C., et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62 (2013), 1084–1093.
37. Bai, P., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13 (2011), 461–468.
38. Bai, P., et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab. 13 (2011), 450–460.
39. Fang, E.F., et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24 (2016), 566–581.
40. Blacher, E., et al. Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 78 (2015), 88–103.
41. Barbosa, M.T., et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21 (2007), 3629–3639.
42. Long, A., et al. CD38 knockout mice show significant protection against ischemic brain damage despite high level poly-ADP-ribosylation. Neurochem. Res. 42 (2017), 283–293.
43. Camacho-Pereira, J., et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23 (2016), 1127–1139.
44. Mills, K.F., et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24 (2017), 795–806.
45. Mouchiroud, L., et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154 (2013), 430–441.
46. Zhang, H., et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352 (2016), 1436–1443.
47. Zhu, X.H., et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2876–2881.
48. Massudi, H., et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 7, 2012, e42357.
49. Balan, V., et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J. Biol. Chem. 283 (2008), 27810–27819.
50. Gomes, A.P., et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155 (2013), 1624–1638.
51. Yoshino, J., et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14 (2011), 528–536.
52. Sugitani, N., et al. XPA: A key scaffold for human nucleotide excision repair. DNA Repair (Amst) 44 (2016), 123–135.
53. States, J.C., et al. Distribution of mutations in the human xeroderma pigmentosum group A gene and their relationships to the functional regions of the DNA damage recognition protein. Hum. Mutat. 12 (1998), 103–113.
54. Karikkineth, A.C., et al. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res. Rev. 33 (2017), 3–17.
55. Lehmann, A.R., Three complementation groups in Cockayne syndrome. Mutat. Res. 106 (1982), 347–356.
56. Scheibye-Knudsen, M., et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20 (2014), 840–855.
57. North, B.J., et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO J. 33 (2014), 1438–1453.
58. Lopez-Otin, C., et al. The hallmarks of aging. Cell 153 (2013), 1194–1217.
59. Kerr, J.S., et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 40 (2017), 151–166.
60. Gong, B., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 34 (2013), 1581–1588.
61. Long, A.N., et al. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol., 15, 2015, 19.
62. Wang, X., et al. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 1643 (2016), 1–9.
63. Liu, D., et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol. Aging 34 (2013), 1564–1580.
64. Kume, S., et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest. 120 (2010), 1043–1055.
65. Zheng, L., et al. Parkin functionally interacts with PGC-1alpha to preserve mitochondria and protect dopaminergic neurons. Hum. Mol. Genet. 26 (2017), 582–598.
66. Palikaras, K., et al. Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans. Nature 521 (2015), 525–528.
67. Menzies, F.M., et al. Compromised autophagy and neurodegenerative diseases. Nat. Rev. Neurosci. 16 (2015), 345–357.
68. Scarffe, L.A., et al. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 37 (2014), 315–324.
69. Birkmayer, J.G., et al. Nicotinamide adenine dinucleotide (NADH)–a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol. Scand. 146:Suppl (1993), 32–35.
70. Lu, L., et al. Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson's disease. Exp. Ther. Med. 8 (2014), 943–950.
71. Lehmann, S., et al. Enhancing NAD+ salvage metabolism is neuroprotective in a PINK1 model of Parkinson's disease. Biol. Open 6 (2016), 141–147.
72. Hammer, M.S., et al. Environmental noise pollution in the United States: developing an effective public health response. Environ. Health Perspect. 122 (2014), 115–119.
73. Brown, K.D., et al. Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20 (2014), 1059–1068.
74. Someya, S., et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143 (2010), 802–812.
75. Kim, H.J., et al. Nicotinamide adenine dinucleotide: an essential factor in preserving hearing in cisplatin-induced ototoxicity. Hear. Res. 326 (2015), 30–39.
76. Kim, H.J., et al. Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell Death Dis., 5, 2014, e1292.
77. Ryu, D., et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci. Transl. Med., 8, 2016 361ra139.
78. Noseworthy, J.H., et al. Multiple sclerosis. N. Engl. J. Med. 343 (2000), 938–952.
79. Shindler, K.S., et al. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 48 (2007), 3602–3609.
80. Gujar, A.D., et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E8247–E8256.
81. Xu, W., et al. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 13 (2015), 533–545.
82. de Picciotto, N.E., et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15 (2016), 522–530.
83. Goodpaster, B.H., et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61 (2006), 1059–1064.
84. Canto, C., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15 (2012), 838–847.
85. Gariani, K., et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63 (2016), 1190–1204.
86. Lee, H.J., et al. Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes. J. Med. Food 18 (2015), 1207–1213.
87. Weissman, L., et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res. 35 (2007), 5545–5555.
88. Maynard, S., et al. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb. Perspect. Med., 5, 2015 a025130.
89. White, R.R., Vijg, J., Do DNA double-strand breaks drive aging?. Mol. Cell 63 (2016), 729–738.
90. Riklis, E., et al. Increased radioprotection attained by DNA repair enhancement. Pharmacol. Ther. 39 (1988), 311–322.
91. Watson, A., et al. Nicotinamide phosphoribosyltransferase in smooth muscle cells maintains genome integrity, resists aortic medial degeneration and is suppressed in human thoracic aortic aneurysm disease. Circ. Res. 120 (2017), 1889–1902.
92. Weidele, K., et al. The NAD+ precursor nicotinic acid improves genomic integrity in human peripheral blood mononuclear cells after X-irradiation. DNA Repair (Amst) 52 (2017), 12–23.
93. Scheibye-Knudsen, M., et al. A high fat diet and NAD+ rescue premature aging in cockayne syndrome. Cell Metab. 20 (2014), 840–855.
94. Shiloh, Y., Ziv, Y., The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14 (2013), 197–210.
95. Sharma, N.K., et al. Intrinsic mitochondrial DNA repair defects in ataxia telangiectasia. DNA Repair (Amst) 13 (2014), 22–31.
96. Iyama, T., Wilson, D.M. 3rd, DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 12 (2013), 620–636.
97. Fang, E.F., et al. Nuclear DNA damage signalling to mitochondria in ageing. Nat. Rev. Mol. Cell Biol. 17 (2016), 308–321.
98. Cerutti, R., et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 19 (2014), 1042–1049.
99. Wu, Z., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 (1999), 115–124.
100. Marino, G., et al. Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15 (2014), 81–94.
101. Matecic, M., et al. A microarray-based genetic screen for yeast chronological aging factors. PLoS Genet., 6, 2010 e1000921.
102. Toth, M.L., et al. Longevity pathways converge on autophagy genes to regulate life span in Caenorhabditis elegans. Autophagy 4 (2008), 330–338.
103. Lee, J.H., et al. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327 (2010), 1223–1228.
104. Deretic, V., et al. Autophagy in infection, inflammation and immunity. Nat. Rev. Immunol. 13 (2013), 722–737.
105. Han, X., et al. AMPK activation protects cells from oxidative stress-induced senescence via autophagic flux restoration and intracellular NAD(+) elevation. Aging Cell 15 (2016), 416–427.
106. Lee, I.H., et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3374–3379.
107. Morselli, E., et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J. Cell Biol. 192 (2011), 615–629.
108. Fang, E.F., Bohr, V.A., NAD+: The convergence of DNA repair and mitophagy. Autophagy 13 (2016), 442–443.
109. Egan, D.F., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331 (2011), 456–461.
110. Lettieri Barbato, D., et al. FoxO1 controls lysosomal acid lipase in adipocytes: implication of lipophagy during nutrient restriction and metformin treatment. Cell Death Dis., 4, 2013, e861.
111. Wang, P., et al. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy 8 (2012), 77–87.
112. Hariharan, N., et al. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ. Res. 107 (2010), 1470–1482.
113. Jang, S.Y., et al. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J. Biol. Chem. 287 (2012), 19304–19314.
114. Fang, E.F., et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24 (2016), 566–581.
115. Conze, D.B., et al. Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum. Exp. Toxicol. 35 (2016), 1149–1160.
116. van de Weijer, T., et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes 64 (2015), 1193–1201.
117. Trammell, S.A., et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun., 7, 2016, 12948.
118. ® – The World's First and Only Commercially Available Form of Nicotinamide Riboside (NR). 2016, ChromaDex.
119. Longo, V.D., Mattson, M.P., Fasting: molecular mechanisms and clinical applications. Cell Metab. 19 (2014), 181–192.
120. Zhao, Y., et al. SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab. 21 (2015), 777–789.
121. Ying, W., et al. NAD+ as a metabolic link between DNA damage and cell death. J. Neurosci. Res. 79 (2005), 216–223.
122. Bieganowski, P., Brenner, C., Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117 (2004), 495–502.
123. Bogan, K.L., Brenner, C., Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28 (2008), 115–130.
124. Nikiforov, A., et al. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286 (2011), 21767–21778.
125. Berger, F., et al. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280 (2005), 36334–36341.
126. Tsubota, K., The first human clinical study for NMN has started in Japan. NPJ Aging Mech. Dis., 2, 2016, 16021.